598 reports of this reaction
1.7% of all VALBENAZINE reports
#16 most reported adverse reaction
PARKINSONISM is the #16 most commonly reported adverse reaction for VALBENAZINE, manufactured by Neurocrine Biosciences, Inc.. There are 598 FDA adverse event reports linking VALBENAZINE to PARKINSONISM. This represents approximately 1.7% of all 34,810 adverse event reports for this drug.
Patients taking VALBENAZINE who experience parkinsonism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PARKINSONISM is a less commonly reported adverse event for VALBENAZINE, but still significant enough to appear in the safety profile.
In addition to parkinsonism, the following adverse reactions have been reported for VALBENAZINE:
The following drugs have also been linked to parkinsonism in FDA adverse event reports:
PARKINSONISM has been reported as an adverse event in 598 FDA reports for VALBENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PARKINSONISM accounts for approximately 1.7% of all adverse event reports for VALBENAZINE, making it a notable side effect.
If you experience parkinsonism while taking VALBENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.